Fresenius Kabi launches generic drug for the treatment of serious fungal infections in the U.S.

Fresenius Kabi announced today the immediate availability in the U.S. of Posaconazole Injection, a generic substitute for Noxafil®*, for the treatment or prevention of serious fungal infections. It is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.

For more information, please see the website of Fresenius Kabi.

*Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.